Get access

Targeting of Multidrug-Resistant Human Ovarian Carcinoma Cells With Anti-P-Glycoprotein Antibody Conjugates

Authors

  • Kirk D. Fowers,

    1. Department of Bioengineering, University of Utah, Salt Lake City, UT 84112, USA
    Search for more papers by this author
  • Jindřich Kopeček

    Corresponding author
    1. Department of Bioengineering, University of Utah, Salt Lake City, UT 84112, USA
    2. Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84112, USA
    • Department of Bioengineering, University of Utah, Salt Lake City, UT 84112, USA.
    Search for more papers by this author

Abstract

A monoclonal antibody (mAb) to P-glycoprotein (Pgp), UIC2, is used as a targeting moiety for N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer/drug [(meso chlorin e6 mono(N-2-aminoethylamide) (Mce6) or doxorubicin (DOX)] conjugates to investigate their cytotoxicity towards the Pgp-expressing human ovarian carcinoma cell line A2780/AD. The binding, internalization, and subcellular trafficking of a fluorescein labeled UIC2 targeted HPMA copolymer are studied and show localization to the plasma membrane with limited internalization. The specificity of the UIC2-targeted HPMA copolymer/drug conjugates are confirmed using the sensitive cell line A2780 that does not express Pgp.

original image
Get access to the full text of this article

Ancillary